| Nivolumab in Previously Untreated Melanoma without BRAF Mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015 | 6103 | 2015 |
| Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma A Younes, AK Gopal, SE Smith, SM Ansell, JD Rosenblatt, KJ Savage, ... Journal of clinical oncology 30 (18), 2183-2189, 2012 | 1747 | 2012 |
| The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP LH Sehn, B Berry, M Chhanabhai, C Fitzgerald, K Gill, P Hoskins, R Klasa, ... Blood 109 (5), 1857-1861, 2007 | 1714 | 2007 |
| Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone NA Johnson, GW Slack, KJ Savage, JM Connors, S Ben-Neriah, S Rogic, ... Journal of clinical oncology 30 (28), 3452-3459, 2012 | 1110 | 2012 |
| The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma KJ Savage, S Monti, JL Kutok, G Cattoretti, D Neuberg, L De Leval, ... Blood 102 (12), 3871-3879, 2003 | 1041 | 2003 |
| Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, ... The lancet oncology 17 (9), 1283-1294, 2016 | 1002 | 2016 |
| ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise … KJ Savage, NL Harris, JM Vose, F Ullrich, ES Jaffe, JM Connors, ... Blood, The Journal of the American Society of Hematology 111 (12), 5496-5504, 2008 | 998 | 2008 |
| Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response S Monti, KJ Savage, JL Kutok, F Feuerhake, P Kurtin, M Mihm, B Wu, ... Blood 105 (5), 1851-1861, 2005 | 977 | 2005 |
| MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy KJ Savage, NA Johnson, S Ben-Neriah, JM Connors, LH Sehn, P Farinha, ... Blood, The Journal of the American Society of Hematology 114 (17), 3533-3537, 2009 | 800 | 2009 |
| Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma JM Connors, W Jurczak, DJ Straus, SM Ansell, WS Kim, A Gallamini, ... New England Journal of Medicine 378 (4), 331-344, 2018 | 753 | 2018 |
| Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival NA Johnson, KJ Savage, O Ludkovski, S Ben-Neriah, R Woods, C Steidl, ... Blood, The Journal of the American Society of Hematology 114 (11), 2273-2279, 2009 | 730 | 2009 |
| Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm … P Armand, A Engert, A Younes, M Fanale, A Santoro, PL Zinzani, ... Journal of Clinical Oncology 36 (14), 1428-1439, 2018 | 710 | 2018 |
| Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study OA O'Connor, B Pro, L Pinter-Brown, N Bartlett, L Popplewell, B Coiffier, ... Journal of Clinical Oncology 29 (9), 1182-1189, 2011 | 698 | 2011 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 694 | 2019 |
| MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers C Steidl, SP Shah, BW Woolcock, L Rui, M Kawahara, P Farinha, ... Nature 471 (7338), 377-381, 2011 | 694 | 2011 |
| Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ... Journal of Clinical Oncology 35 (2), 226-235, 2017 | 573 | 2017 |
| Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study OA O'Connor, S Horwitz, T Masszi, A Van Hoof, P Brown, J Doorduijn, ... Journal of Clinical Oncology 33 (23), 2492-2499, 2015 | 501 | 2015 |
| Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification KJ Savage, M Chhanabhai, RD Gascoyne, JM Connors Annals of Oncology 15 (10), 1467-1475, 2004 | 499 | 2004 |
| Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project DD Weisenburger, KJ Savage, NL Harris, RD Gascoyne, ES Jaffe, ... Blood, The Journal of the American Society of Hematology 117 (12), 3402-3408, 2011 | 498 | 2011 |
| Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma AJ Al-Tourah, KK Gill, M Chhanabhai, PJ Hoskins, RJ Klasa, KJ Savage, ... Journal of Clinical Oncology 26 (32), 5165-5169, 2008 | 455 | 2008 |
